

Pharmaceutical Industry in China - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

<https://marketpublishers.com/r/P39AE778E2DEN.html>

Date: April 2014

Pages: 153

Price: US\$ 3,400.00 (Single User License)

ID: P39AE778E2DEN

Abstracts

'Pharmaceutical Industry China – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges' provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 199 tables & figures within 153 pages. The Chinese biopharmaceutical market is presented as follows:

By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)

By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:

Company financials, sales & revenue figures – historical to Q2 2013

China GDP, economic growth, export (bulk drug, formulations) figures

Indian health expenditure as a function of GDP

Growth change figures of emerging and developing countries (India, Russia, China, Brazil)

Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)

Projected figures of strategic emerging industry GDP percentage contribution

SWOT, Economic and Business Environment specifics include:

Key strengths, weaknesses and threats influencing leading player position within the market

Top Five Contract Pharmaceutical Export Markets of China

Major players within China's leading therapeutic markets (e.g., cancer, allergy, liver disease)

Multinational penetration into the Chinese Pharma Market

Comprehensive product portfolios, R&D activity and pipeline therapeutics

M&A activity and future strategies of top Chinese pharmacos

Economic indicators, trade policy, merchandise and commercial trade statistics

Gross Domestic Product of China, historic and projection analysis

Chinese economic outlook in comparison to advanced economies

Three Tier 'Pharmerging' Markets with Potential for Significant Growth

Prescription drug sales distribution channels in China

Major biogeneric products in China

This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.

Amoytop Biotech

Active Pharmaceutical Products

Beijing Continent Pharmaceuticals

FusoGen Pharmaceuticals

Shanghai Huaguan Biochip

SiBiono GeneTech

Abbott

AstraZeneca

Boehringer Ingelheim

Eli Lilly

GlaxoSmithKline

Johnson & Johnson Medical

Merck

Novartis

Pfizer

Roche

Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends

that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

What you will gain:

An in-depth understanding of the Chinese biopharmaceutical market and it's environment

Current market facts, figures and product lines of key players in the industry

An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market

Knowledge of how the Chinese pharma market will integrate into the global healthcare market

Information on key regulatory and government policies

Data on levels of private and publically funded biopharma studies in China

Strategies on how to adapt and restructure current business models to this industry

This report tackles key concerns to the Chinese biopharmaceutical market such as:

Lack of regulatory policy and legislation

Reimbursement schemes and payers concerns

Funding and government sponsorship issues

International scepticism of Chinese safety and efficacy therapeutic profiles

This report will tell you if the companies mentioned are:

Strong, competitive players

Pooling their resources for specific growth and therapeutic areas

Investing strategically in R&D

Have a history of strategic M&A activity

Benefits of Investing in our Cutting-Edge Reports:

Clients receive complementary content* with mid-level and enterprise wide licences

Post-sale complementary consultation with senior expert analyst is included

Use of tables and figures in your own reports and presentations is permitted

Each report provides straight-talking strategic analysis & sector intelligence

All reports are updated each quarter to give you the most up-to-date information

WE WANT TO MAXIMIZE YOUR BUSINESS POTENTIAL

Subject to terms & conditions negotiated with Kelly Scientific Publications prior to sale

Contents

1.0 SUMMARY

- 1.1 Objectives of Report
- 1.2 Scope of Study
- 1.3 Data Sources and Methodology
- 1.4 Key Findings and Observations
- 1.5 Executive Summary

2.0 CHRONIC DISEASE PREVALENCE STATISTICS

3.0 BUSINESS ENVIRONMENT

- 3.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics
- 3.2 Gross Domestic Product of China, Historic and Projection Analysis
- 3.3 Annual Health Expenditure in China, Historic and Projected Analysis
- 3.4 Global and Chinese Economic Outlook 2010-2013
- 3.5 Chinese Economic Outlook in Comparison to Emerging Markets and Developing Countries
- 3.6 Chinese Economic Outlook in Comparison to Advanced Economies (US, Europe)

4.0 CHINESE PHARMACEUTICAL MARKET

- 4.1 Market Overview
- 4.2 Main Players in China's Pharmaceutical Industry
- 4.3 Anti-Allergy Drug Market
- 4.4 Asthma Drug Market
- 4.5 Benign Prostate Hyperplasia Drug Market
- 4.6 Anti-Depressant Drug market
- 4.7 Dermatitis Drug Market
- 4.8 Diabetes Drug Market
- 4.9 Hypertension Drug Market
- 4.10 Dyslipidaemia Drug Market
- 4.11 Senile Dementia Drug Market
- 4.12 Cancer Drug Market
- 4.13 Rheumatoid Arthritis Drug Market
- 4.14 Ophthalmological Drug Market

- 4.15 Liver Disease Drug Market
- 4.16 Antibiotic Drug Market

5.0 GOVERNMENT AND REGULATION ENVIRONMENT

- 5.1 12th Five Year Plan
- 5.2 Intellectual Property for Pharmaceuticals in China
- 5.3 State Food and Drug Administration (SFDA)
- 5.4 Pharmaceutical Distribution Process in China

6.0 CHINA – THIRD LARGEST PHARMA MARKET 2012

- 6.1 China – At the Forefront of Emerging Markets
- 6.2 Generic Medication Market and China
- 6.3 Novel Product Drug Development
- 6.4 Drug Development Cost and Outsourcing
- 6.5 Drug Development Case Study - Beijing Continent Pharmaceuticals
- 6.6 China's Pharmaceutical Export Market
- 6.7 Spot Light - China Medical City Taizhou

7.0 GLOBAL PHARMACEUTICAL COMPANIES INTEREST IN CHINA

- 7.1 Abbott China
- 7.2 AstraZeneca China
- 7.3 Bayer China
- 7.4 Boehringer Ingelheim China
- 7.5 Eli Lilly China
- 7.6 GlaxoSmithKline China
- 7.7 Johnson & Johnson Medical China
- 7.8 Merck China
- 7.9 Novartis China
- 7.10 Novo Nordisk China
- 7.11 Pfizer China
 - 7.11.1 Pfizer China R&D Centre
 - 7.11.2 Pfizer China Products
 - 7.11.3 Pfizer Financials
 - 7.11.4 Pfizer Global
- 7.12 Roche China
- 7.13 Sanofi China

8.0 CHINESE PHARMACEUTICAL COMPANIES

- 8.1 Amoytop Biotech
- 8.2 Active Pharmaceutical Products
 - 8.2.1 Research and Development
 - 8.2.2 Financial Information
- 8.3 Beijing Continent Pharmaceuticals
- 8.4 FusoGen Pharmaceuticals
 - 8.4.1 Financial Information
- 8.5 Shanghai Huaguan Biochip
 - 8.5.1 Financial Information
- 8.6 SiBiono GeneTech
 - 8.6.1 Financial Information
- 8.7 Sinovac Biotech
 - 8.7.1 Financial Information
 - 8.7.2 New Products
 - 8.7.3 Split Virion Pandemic Influenza Vaccine
 - 8.7.4 RabEnd
 - 8.7.5 Pipeline Portfolio
 - 8.7.6 EV71 virus Vaccine
 - 8.7.7 Pneumococcal Conjugate Vaccine
 - 8.7.8 Pneumococcal Polysaccharide Vaccine
 - 8.7.9 Varicella Vaccine
 - 8.7.10 Measles, Mumps and Rubella Vaccines
 - 8.7.11 Rotavirus Vaccine

9.0 DRIVERS, RESTRAINTS, CHALLENGES AND OPPORTUNITY ANALYSIS

- 9.1 Key Drivers of the Pharmaceutical Market in China
- 9.2 Key Restraints of the Pharmaceutical Market in China
- 9.3 Challenges of the Pharmaceutical Industry in China
- 9.4 Opportunities Within BioPharma China

List Of Tables

LIST OF TABLES

Table 2.1: Most Prominent Cancer Manifestations in China

Table 2.2: Top Fifty Diseases in China Today (non-cancer)

Table 2.3: Top Infectious Disease States in China Today

Table 3.1: World Trade Organisation Basic Indicators on China

Table 3.2: World Trade Organisation Trade Policy of China

Table 3.3: World Trade Organisation Merchandise Trade Statistics: China

Table 3.4: World Trade Organisation Commercial Services Trade Statistics: China

Table 3.5: Summary of International Monetary Fund Members' Quota, Reserve Position, SDR Holdings, Outstanding Credit, Recent Lending Arrangements, Projected Payments Due and Monthly Historical Transactions of China

Table 3.6: China Statistics

Table 4.1: Top Global Pharma Markets 2003-2013

Table 4.2: Major Players in China's Anti-Allergy Drug Market

Table 4.3: Major Players in China's Asthma Drug Market

Table 4.4: Major Players in China's Benign Prostate Hyperplasia (BPH) Drug Market

Table 4.5: Major Players in China's Anti-Depressant Drug Market

Table 4.6: Prescription Dermatitis Drug Industry Sub-Markets and Associated Therapeutics

Table 4.7: Top Prescription Dermatitis Drugs on the Chinese Market

Table 4.8: Major Players in China's Dermatitis Drug Market

Table 4.9: Major Players in China's Diabetic Drug Market

Table 4.10: Major Players in China's Hypertension Drug Market

Table 4.11: Major Players in China's Dyslipidaemia Drug Market

Table 4.12: Major Players in China's Senile Dementia Drug Market

Table 4.13: Major Players in China's Cancer Drug Market

Table 4.14: Major Players in China's Rheumatoid Arthritis Drug Market

Table 4.15: Major Players in China's Ophthalmological Drug Market

Table 4.16: Major Players in China's Liver Disease Drug Market

Table 4.17: Major Players in China's Antibiotic Drug Market

Table 5.1: Seven Strategic Emerging Industries of China's 12th Five Year Plan 2011-2015

Table 5.2: Outline of the Chinese Promotion Plan for the Implementation of the National Intellectual Property Strategy, 2012

Table 5.3: Challenges facing the Pharmaceutical Distribution Business in China

Table 5.4: Prescription Drug Sales Distribution Channels in China

Table 6.1: Major Biogeneric Products in China

Table 6.2: Imported Therapeutics with Administrative Protection in China

Table 6.3: Expired Proprietary Pharmaceuticals in China

Table 6.4: Reasons Why Multinational Companies Seek CMO's in China

Table 6.5: Comparison of Clinical Trial Cost between China and the USA

Table 6.6: Five Functional Districts of China Medical City

Table 6.7: Five Key R&D and Manufacturing Areas within China Medical City

Table 7.1: Top Multinational Company Performance, China

Table 7.2: Abbott Areas of Expertise

Table 7.3: Abbott Key Global Products

Table 7.4: AbbVie (Abbott) Speciality Care Products Holding Market-Leading Positions

Table 7.5: Abbott China Anaesthesia Product Profile

Table 7.6: Abbott China Cardiovascular Product Profile

Table 7.7: Abbott China Vaccine Product Profile

Table 7.8: Abbott China Digestion Product Profile

Table 7.9: Abbott China HIV Product Profile

Table 7.10: Abbott Rheumatology HIV Product Profile

Table 7.11: Abbott China Gynaecological Product Profile

Table 7.12: Abbott China Urological Product Profile

Table 7.13: Abbott China Liver Disease Product Profile

Table 7.14: Abbott China Diagnostic Product Profile

Table 7.15: Abbott China Molecular Diagnostic Product Profile

Table 7.16: Abbott Blood Glucose Meter Product Profile

Table 7.17: Abbott Cardiovascular Product Profile

Table 7.18: Abbott Rapid Bedside Diagnostic/ Point of Care Product Profile

Table 7.19: Important Milestones in AstraZeneca China's History

Table 7.20: AstraZeneca China Anaesthetic Range of Products

Table 7.21: AstraZeneca China Cardiovascular and Metabolism Range of Products

Table 7.22: AstraZeneca China Gastrointestinal Range of Products

Table 7.23: AstraZeneca China Infection Range of Products

Table 7.24: AstraZeneca China Neurology Range of Products

Table 7.25: AstraZeneca China Oncology Range of Products

Table 7.26: AstraZeneca China Respiratory Range of Products

Table 7.27: AstraZeneca Top Branded Pharmaceuticals Globally

Table 7.28: AstraZeneca Sales (US\$ Mil) of Top Branded Pharmaceuticals Globally

Table 7.29: Bayer China Important Milestones

Table 7.30: Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in China

Table 7.31: Bayer - Leading Therapeutics in China

Table 7.32: Bayer Top Selling Consumer Health Products

- Table 7.33: Boehringer Ingelheim Major Products in China
- Table 7.34: Main Therapeutic Areas of Interest to Boehringer Ingelheim China
- Table 7.35: Global Therapeutic Pipeline, Boehringer Ingelheim
- Table 7.36: Major Global Boehringer Ingelheim Therapeutic Products
- Table 7.37: Eli Lilly Top Selling Global Branded Pharmaceuticals 2012-2013 (\$ billion) and Percentage Change
- Table 7.38: GlaxoSmithKline Prescription Portfolio and Indications in China
- Table 7.39: GlaxoSmithKline Vaccine Portfolio and Indications in China
- Table 7.40: GlaxoSmithKline Over the Counter Portfolio and Indications in China
- Table 7.41: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, FY2012-2013
- Table 7.42: GlaxoSmithKline Global Vaccine Sales FY2012-2013
- Table 7.43: Significant Milestones in Johnson and Johnson China History
- Table 7.44: Johnson & Johnson Pharmaceutical Segment Sales (US\$ Billion) by Therapeutic Area and Percentage Change, 2012-2013
- Table 7.45: Merck Serono Pharmaceutical Key Therapeutic Areas in China
- Table 7.46: Merck Serono Fertility and Infertility Therapeutic Portfolio in China
- Table 7.47: Merck Serono Therapeutic Portfolio in China
- Table 7.48: Merck Pharmaceutical Hong Kong Therapeutic Portfolio
- Table 7.49: Merck Global Pharmaceutical, Animal Health and Consumer Health Sales 2012-2013
- Table 7.50: Merck Top Ten Global Pharmaceutical Brand Sales 2012-2013
- Table 7.51: Range of Diabetic Products from Novo Nordisk China
- Table 7.52: QUICKFACTs - Pfizer China
- Table 7.53: Important Milestones – Pfizer China
- Table 7.54: Pfizer China – Range of Infectious Disease Therapeutics for Chinese Health Care Market
- Table 7.55: Pfizer China – Range of Mental Health Products for Chinese Health Care Market
- Table 7.56: Pfizer China – Range of Genitourinary Products for Chinese Health Care Market
- Table 7.57: Pfizer China – Range of Endocrine Products for Chinese Health Care Market
- Table 7.58: Pfizer China – Range of Women’s Health Products for Chinese Health Care Market
- Table 7.59: Pfizer China – Range of Cardiovascular Disease Products for Chinese Health Care Market
- Table 7.60: Pfizer China – Range of Oncology Products for Chinese Health Care Market
- Table 7.61: Pfizer – Key Consumer Healthcare Global Products

- Table 7.62: Pfizer – Key Speciality Care Global Products
- Table 7.63: Pfizer – Key Oncology Global Products
- Table 7.64: Pfizer – Key Global Established Products
- Table 7.65: Pfizer – Key Innovative Products in Emerging Markets
- Table 7.66: Pfizer – Key Animal Health Global Products
- Table 7.67: Pfizer Product Sales with Significant Impact on Revenues 2012:2013 Comparison
- Table 7.68: Roche Pharmaceuticals Product List in China
- Table 7.69: Roche Global Sales (CHF Millions) by Therapeutic Area, 2012 & 2013 and Percentage Change (CER)
- Table 7.70: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2011, 2012, 2013 and Percentage Change (CER)
- Table 7.71: Seven Growth Platforms of Sanofi China
- Table 7.72: Key Therapeutic Areas of Sanofi China
- Table 8.1: Important Milestones in Amoytop Biotech's Development
- Table 8.2: Amoytop Biotech – Main Objectives of Research and Development Division
- Table 8.3: Amoytop Biotech – Panel of Recombinant Protein Therapeutics in Clinical Studies
- Table 8.4: Amoytop Biotech Portfolio of Patented Y-Shaped Branched Pegylated Recombinant Protein Therapeutics within Clinical Investigation in China
- Table 8.5: Current Recombinant protein therapeutics by Amoytop Biotech
- Table 8.6: Active Pharmaceutical Product Portfolio of Amoytop Biotech
- Table 8.7: Milestones Achieved by FusoGen Pharmaceuticals
- Table 8.8: Research and Development Sub-groups of FusoGen Pharmaceuticals
- Table 8.9: Shanghai Huaguan Biochip Rapid Test Portfolio
- Table 8.10: Shanghai Huaguan Biochip Multi Drugs of Abuse Test Profile
- Table 8.11: Shanghai Huaguan Biochip Infectious Disease Test Portfolio
- Table 8.12: Shanghai Huaguan Biochip Diagnostic Test Portfolio
- Table 8.13: Shanghai Huaguan Biochip Laboratory Service Portfolio
- Table 8.14: Intracellular Functions of the Gene Therapy Agent, Gendicine by SiBiono GeneTech
- Table 8.15: Gendicine - Potential Oncology Indications for Future Approval
- Table 8.16: Current Human Vaccine Portfolio of Sinovac Biotech
- Table 8.17: Important Milestones in the History of Sinovac Biotech
- Table 8.18: Pipeline Portfolio of Sinovac Biotech
- Table 8.19: Total Sales Figures Sinovac Biotech 2007-2012
- Table 9.1: Key Drivers of the Pharmaceutical Market in China
- Table 9.2: Key Restraints of the Pharmaceutical Market in China
- Table 9.3: Key Challenges of the Pharmaceutical Market in China

Table 9.4: Patent Expirations of Selected Top Brand Name Therapeutics by 2020

Table 9.5: Leading Pharmaceutical Areas with Significant Opportunities in China

List Of Figures

LIST OF FIGURES

- Figure 2.1: Proportional (%) Mortality Rate of Total Deaths in China, All Ages
- Figure 3.1: China GDP Figures 2006-2015
- Figure 3.2: Annual Health Expenditure in China 2006-2015
- Figure 3.3: Global, Emerging Market & Developing Countries Economic Growth Change 2010-2013
- Figure 3.4: Global, Emerging Market & Developing Countries & China Economic Growth Change 2010-2013
- Figure 3.5: Global, Emerging Market & Developing Countries & Russia Economic Growth Change 2010-2013
- Figure 3.6: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010-2013
- Figure 3.7: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013
- Figure 3.8: Global, US and Germany Economic Growth 2010-2013
- Figure 3.9: US and UK Gross Domestic Product per capita Forecast 2010-2017
- Figure 3.10: Global, France and Italy Economic Growth 2010-2013
- Figure 3.11: France, Germany and Italy Gross Domestic Product per capita Forecast 2010-2017
- Figure 3.12: Global, UK and Spain Economic Growth 2010-2013
- Figure 3.13: Global, Japan and Canada Economic Growth 2010-2013
- Figure 3.14: China, Brazil and India Gross Domestic Product per capita Forecast 2010-2017
- Figure 4.1: The Chinese Healthcare Industry by Sector, 2011
- Figure 5.1: Projected Figures of Strategic Emerging Industry GDP Percentage Contribution 2011-2020
- Figure 5.2: State Drug and Food Administration, China, Application and Approval Procedure for Imported Drugs
- Figure 5.3: State Drug and Food Administration, China, Application and Approval Procedure for Clinical Trials
- Figure 5.4: Revenue Share (Percentage) of Major Players in Chinese Pharmaceutical Distribution Market
- Figure 5.5: Revenue Share (Billion \$) of Major Players in Chinese Pharmaceutical Distribution Market
- Figure 6.1: Three Tier 'Pharmerging' Markets with Potential for Significant Growth
- Figure 6.2: Number of Investigational New Drug Applications in China 2003-2010

Figure 6.3: Number of New Drug Applications in China 2003-2010

Figure 6.4: Current Number of Novel Therapeutics in Phase I, Phase II and Phase III Clinical Trials in China

Figure 6.5: Percentage of Clinical Trial Drug by Disease State

Figure 6.6: China's Regional Pharmaceutical Processing Trade Export Market Share Percentage

Figure 6.7: Contract Amount of China's Regional Pharmaceutical Processing Trade Export

Figure 6.8: Top Five Contract Pharmaceutical Export Markets of China

Figure 7.1: Abbott Laboratories Geographic Distribution of Revenue –USA, Established and Emerging Markets

Figure 7.2: Abbott Laboratories Established and Emerging Revenue Share (%) 2012-2015

Figure 7.3: Abbott – Business Specialization Strategy 2012: Diversified Medical Products and Research-Based Pharmaceuticals

Figure 7.4: Abbott Diversified Medical Product Portfolio

Figure 7.5: AstraZeneca Sales Revenue (US\$ Millions) in China, 2010-2013

Figure 7.6: AstraZeneca Global Revenue (Billions) by Geographic Area: USA, Western Europe, Emerging Markets 2012

Figure 7.7: AstraZeneca Cardiovascular Product (Atacand, Crestor, Seloken/Toprol-XL) Global Sales 2010-2012

Figure 7.8: AstraZeneca Gastrointestinal Product (Nexium) Global Sales 2010-2012

Figure 7.9: AstraZeneca Infection Product (Synagis) Global Sales 2010-2012

Figure 7.10: AstraZeneca Neuroscience Product (Seroquel-IR, -XR) Global Sales 2010-2012

Figure 7.11: AstraZeneca Oncology Product (Zoladex) Global Sales 2010-2012

Figure 7.12: AstraZeneca Respiratory/Inflammation Product (Pulmicort, Symbicort) Global Sales 2010-2012

Figure 7.13: Boehringer Ingelheim Oncology Compounds in Development

Figure 7.14: GlaxoSmithKline Total Sales, Pharmaceutical, Vaccine and Consumer Healthcare Sales 2012-2013 (£ Billions)

Figure 7.15: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, 2012-2013

Figure 7.16: GlaxoSmithKline Global Vaccine Sales by Therapeutic Area, 2012-2013

Figure 7.17: GlaxoSmithKline Global Sales by Geographic Region – USA, Europe, Emerging Markets, Japan, 2012-2013

Figure 7.18: Johnson & Johnson Pharmaceutical Segment Sales (US\$ Billion) by Therapeutic Area, 2012-2013

Figure 7.19: Novartis International Sales (%) by Geographic Region, 2012-2013

Figure 7.20: Novartis International Sales (US\$ Millions) by Geographic Region, 2012-2013

Figure 7.21: Novo Nordisk Total China Sales 2009-2013

Figure 7.22: Novo Nordisk Total Diabetes Care Market Sales Performance (DKK Millions) China 2010-2013

Figure 7.23: Novo Nordisk Diabetes Care (NovoRapid/NovoLog, NovoMix/NovoLog Mix, Levemir, Modern Insulin, Human Insulin, Victoza) Sales Performance (DKK Millions) China 2010-2013

Figure 7.24: Business Sectors – Pfizer China

Figure 7.25: Roche Total Global Sales (CHF Millions) 2012-2013

Figure 7.26: Roche Global Sales (CHF Millions) by Therapeutic Area, 2012-2013

Figure 7.27: Roche Pharmaceutical Division Emerging Market Total Sales 2012-2013

Figure 7.28: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2012-2013

Figure 7.29: Sanofi Geographic Market Share (%) – Emerging Markets, USA and Western Europe 2012

Figure 7.30: Sanofi Geographic Market Share (%) –China, Russia and USA 2012

Figure 8.1: FusoGen Pharmaceuticals Product Pipeline and Clinical Trial Progression

Figure 8.2: Shanghai Huaguan Biochip Serial Analysis of Gene Expression (SAGE) Service

Figure 8.3: Total Sales Figures Sinovac Biotech 2007-2012

Figure 8.4: Percentage of Sales Attributed to Healive Vaccine, 2009-2012

Figure 8.5: Reported Sales of Healive Vaccine, 2009-2012

Figure 8.6: Reported Sales of Bilive Vaccine, 2009-2012

Figure 8.7: Reported Sales of Anflu Vaccine, 2009-2012

Figure 8.8: Reported Sales of Panflu Vaccine, 2009-2011

COMPANIES MENTIONED

Amoytop Biotech

Active Pharmaceutical Products

Beijing Continent Pharmaceuticals

FusoGen Pharmaceuticals

Shanghai Huaguan Biochip

SiBiono GeneTech

Abbott

AstraZeneca

Boehringer Ingelheim

Eli Lilly

GlaxoSmithKline
Johnson & Johnson Medical
Merck
Novartis
Pfizer
Roche

I would like to order

Product name: Pharmaceutical Industry in China - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

Product link: <https://marketpublishers.com/r/P39AE778E2DEN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P39AE778E2DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970